




EMLc
ATC codes: **A02BA02**

| | |
|---|---|
| Indication | Peptic ulcer, site unspecified ICD11 code: DA61 |
| INN | Ranitidine |
| Medicine type | Chemical agent |
| List type | Core (EML) (EMLc) |
| Formulations | Oral > Liquid: 75 mg per 5 mL (as hydrochloride) Oral > Solid: 150 mg (as hydrochloride) Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride) |
| EML status history | First added in 2003 (TRS 920) Changed in 2007 (TRS 950) Changed in 2021 (TRS 1035) |
| Sex | All |
| Age | Also recommended for children |
| Therapeutic alternatives | Medicines within the same pharmacological class can be used |
| Therapeutic alternatives limitations | Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations) |
| Therapeutic alternatives limitations for EMLc | Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations) |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  |
| Wikipedia | Ranitidine  |
| DrugBank | Ranitidine  |

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, A02BA H2-receptor antagonists (excluding combinations), be specified as therapeutic alternatives under the square box listing for ranitidine on the EML and EMLc.

